This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, C. E.
Right arrow Articles by Kumar, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, C. E.
Right arrow Articles by Kumar, M. L.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 100 No. 5 November 1997, pp. 761-766

A Long-term Prospective Study of Varicella Vaccine in Healthy Children

Received Feb 18, 1997; accepted May 7, 1997.

Candice E. Johnson*, Terry Stancin*, Deborah Fattlar*, Leonard P. Rome§, , and Mary L. Kumar*

From the * Department of Pediatrics, Case Western Reserve School of Medicine at MetroHealth Medical Center, Cleveland Ohio; and § University Primary Care Group of Rainbow Babies and Children's Hospital, Cleveland, Ohio.

Background.  Studies in Japan and the United States have shown that varicella vaccine is both safe and efficacious. In 1984, we undertook a 10-year prospective study using a research lot of Oka/Merck varicella vaccine to assess antibody persistence and breakthrough chickenpox rates. In 1987, we began a similar prospective study with lots made in production facilities that ended after 6 years because many children were given a second dose. The purpose of this study is to report humoral antibody persistence and breakthrough chickenpox rates after 6 to 10 years of prospective follow-up.

Methods.  One hundred forty-three seronegative children received a research lot (950 plaque-forming units/dose) with 97.9% seroconversion by an assay for fluorescent antibody to membrane antigen (FAMA). One hundred thirty-eight children received production lots (1145 to 3265 plaque-forming units/dose) with 93.5% seroconversion. Yearly chickenpox exposure surveys were completed by phone, and children were seen by a study nurse whenever chickenpox was suspected. A subset in each group had serum collected every 2 years and tested for FAMA antibody.

Results.  In the research group there have been 25 cases of chickenpox in 137 seroconverters in a period of more than 10 years (yearly rate of 1.7%). In the production lot group there have been 22 cases of chickenpox in 129 seroconverters in a 6-year period (yearly rate of 2.8%). In the research group the median titer rose from 1:16 to 1:64 between 1 and 10 years. In the production group, the median titer did not change between 1, 2, and 4 years. Median antibody titers were compared between the research and production groups at 1, 2, and 4 years and did not differ. The rate of development of modified chickenpox has not increased with time since vaccination, and neither has the case severity. Children with FAMA titers <= 8 at 6-weeks' postvaccination were four times more likely to develop chickenpox than those with titers >= 64.

Conclusions.  1) Modified chickenpox has occurred in approximately 2% to 3% of vaccinees per year, regardless of the vaccine lot given. 2) FAMA titers have risen between 1 and 10 years in research lot recipients and remained the same in production lot recipients. 3) The likelihood of modified chickenpox developing is inversely related to the 6-week postvaccination FAMA titer.

Key words: varicella vaccine, chickenpox, varicella zoster.




This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
S. Hambleton and A. A. Gershon
Preventing Varicella-Zoster Disease
Clin. Microbiol. Rev., January 1, 2005; 18(1): 70 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. I. Staprans, A. P. Barry, G. Silvestri, J. T. Safrit, N. Kozyr, B. Sumpter, H. Nguyen, H. McClure, D. Montefiori, J. I. Cohen, et al.
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein
PNAS, August 31, 2004; 101(35): 13026 - 13031.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
B. D. Tugwell, L. E. Lee, H. Gillette, E. M. Lorber, K. Hedberg, and P. R. Cieslak
Chickenpox Outbreak in a Highly Vaccinated School Population
Pediatrics, March 1, 2004; 113(3): 455 - 459.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
J. Breuer
Live attenuated vaccine for the prevention of varicella-zoster virus infection: does it work, is it safe and do we really need it in the UK?
J. Med. Microbiol., January 1, 2003; 52(1): 1 - 3.
[Full Text] [PDF]

Home page
 NEJMHome page
K. Galil, B. Lee, T. Strine, C. Carraher, A. L. Baughman, M. Eaton, J. Montero, and J. Seward
Outbreak of Varicella at a Day-Care Center despite Vaccination
N. Engl. J. Med., December 12, 2002; 347(24): 1909 - 1915.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
M R Wills, A J Carmichael, and J G P Sissons
Vaccines against persistent DNA virus infections
Br. Med. Bull., July 1, 2002; 62(1): 125 - 138.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
P. H. Dennehy
Active Immunization in the United States: Developments over the Past Decade
Clin. Microbiol. Rev., October 1, 2001; 14(4): 872 - 908.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S A Skull and E E L Wang
Current topic: Varicella vaccination{---}a critical review of the evidence
Arch. Dis. Child., August 1, 2001; 85(2): 83 - 90.
[Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
D. A. Clements, J. I. Zaref, C. L. Bland, E. B. Walter, and P. M. Coplan
Partial Uptake of Varicella Vaccine and the Epidemiological Effect on Varicella Disease in 11 Day-Care Centers in North Carolina
Arch Pediatr Adolesc Med, April 1, 2001; 155(4): 455 - 461.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Vazquez, P. S. LaRussa, A. A. Gershon, S. P. Steinberg, K. Freudigman, and E. D. Shapiro
The Effectiveness of the Varicella Vaccine in Clinical Practice
N. Engl. J. Med., March 29, 2001; 344(13): 955 - 960.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. M. Arvin
Varicella Vaccine -- The First Six Years
N. Engl. J. Med., March 29, 2001; 344(13): 1007 - 1009.
[Full Text] [PDF]

Home page
 PediatricsHome page
K. B. Laupland, H. D. Davies, D. E. Low, B. Schwartz, K. Green, the Ontario Group A Streptococcal Study Group, and A. McGeer
Invasive Group A Streptococcal Disease in Children and Association With Varicella-Zoster Virus Infection
Pediatrics, May 1, 2000; 105(5): 60e - 60.
[Abstract] [Full Text]

Home page
 PediatricsHome page
Committee on Infectious Diseases
Varicella Vaccine Update
Pediatrics, January 1, 2000; 105(1): 136 - 141.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. L. Slack, G. C. Allen, J. E. Morrison, K. C. Garren, and M. G. Roback
Post-Varicella Epiglottitis and Necrotizing Fasciitis
Pediatrics, January 1, 2000; 105(1): e13 - e13.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
A. GERSHON
Varicella: to vaccinate or not to vaccinate?
Arch. Dis. Child., December 1, 1998; 79(6): 470 - 471.
[Full Text]

Home page
 Arch Pediatr Adolesc MedHome page
R. D. Newman and J. A. Taylor
Reactions of Pediatricians to the Recommendation for Universal Varicella Vaccination
Arch Pediatr Adolesc Med, August 1, 1998; 152(8): 792 - 796.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. W. Spingarn, J. A. Benjamin, and H. C. Meissner
Universal Vaccination against Varicella
N. Engl. J. Med., March 5, 1998; 338(10): 683 - 684.
[Full Text]

Home page
 Journal Watch DermatologyHome page
Long-Term Study of Varicella Vaccine
Journal Watch Dermatology, December 1, 1997; 1997(1201): 13 - 13.
[Full Text]

Home page
 JWatch GeneralHome page
LONG-TERM STUDY OF VARICELLA VACCINE
Journal Watch (General), November 7, 1997; 1997(1107): 7 - 7.
[Full Text]